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Rapamycin suppresses endothelial proliferation and migration, which leads to delayed re-endothel-
ialization in the rapamycin-eluted stents that are used in coronary heart disease patients. Because
microRNAs (miRs) play important roles in endothelial angiogenesis, we tested the hypothesis that
rapamycin induces endothelial suppression, partly through pathways that involve miRs. Rapamycin
treatment increased the expression of miR-21 in HUVECs. The downregulation of miR-21 by inhib-
itors abolished the negative effects of rapamycin on endothelial cell growth and mobility. RhoB was
conﬁrmed as a direct target gene of miR-21. Knockdown of Raptor by siRNA mimicked the effects of
rapamycin on miR-21 expression. Our study provides a new explanation of the mechanism of rap-
amycin-mediated inhibition of endothelial proliferation and migration.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction rapamycin treatment (>24 h) could impair the mobility of endo-Rapamycin (sirolimus) is a macrocyclic lactone antibiotic. Be-
cause it can suppress the proliferation and migration of vascular
smooth muscle cells (VSMCs) [1], rapamycin is widely used in drug
eluting stents (DES) to prevent in-stent restenosis (ISR) after percu-
taneous coronary intervention. However, recent clinical trials re-
vealed that patients who received rapamycin-eluting stents
implantation presented with higher rates of late stent thrombosis
(LST), compared to patients who received bare-metal stents [2,3].
This is due to the ability of rapamycin to impair the proliferation
and migration of vascular endothelial cells, which leads to a de-
layed re-endothelialization of stent struts [4]. This disadvantage
has limited the use of rapamycin in DES [5].
The mechanism of the inhibitory effects of rapamycin on endo-
thelial proliferation and migration has been previously discussed.
The mammalian target of rapamycin complex1 (mTORC1) is com-
prised of GbL, mammalian target of rapamycin (mTOR) and Raptor.
mTORC2 is comprised similarly of GbL and mTOR, though Rictor is
substituted for Raptor. Once bound to FKBP12, rapamycin can di-
rectly inhibit mTORC1 signalling, which leads to a total arrest of
transcription, ribosome biogenesis, translation initiation [6], and
stop cell cycle at the G0/G1 phase in endothelial cells [7]. mTORC2
was once thought to be insensitive to rapamycin and to control the
actin cytoskeleton [8]; however, later studies revealed that rapa-
mycin could also inhibit mTORC2 signalling and that long-termthelial cells through the mTORC2-p27(kip) pathway [9]. Although
all these studies seemed to provide answers to the question of
how rapamycin mediated the prevention of endothelial cell prolif-
eration or migration, more recently, new and deeper insights into
these mechanisms have been indicated.
MicroRNAs (miRNAs, miRs) are a class of endogenous small non-
codingRNAs that areapproximately19–22bases in length [10].miRs
can regulate gene expression widely at the post-transcriptional
level, mostly by targeting the 30UTR of mRNAs [11]. miRs have been
reported to play large roles in several functions of endothelial cells,
includingproliferation [12],migration [13], angiogenesis [14], senes-
cence [15] and survival [16]. Recent studies have revealed direct
connections between miRs and mTORC. Uesugi et al. reported that
miR-218 targets the mTORC component Rictor in oral cancer cells
[17]. Chen et al. found thatmiR-101mediates the suppressive effects
of laminar shear stress on mTOR expression in vascular endothelial
cells [18]. These reports of feedback between miRs and the mTOR
complex indicate that miRs may be involved in rapamycin-induced
regulation in endothelial cells. In the present study, we investigated
whether miRs have a potential effect on the rapamycin-induced
inhibition of proliferation and migration in endothelial cells.
2. Materials and methods
2.1. Cell culture and chemicals
Human umbilical vein endothelial cells (HUVECs) were ob-
tained from ScienCell (Carlsbad, CA, USA). Cells were cultured in
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foetal bovine serum (FBS) and were kept in a humidiﬁed incubator
that was maintained at 37 C and supplied with 5% CO2 and 95%
air. Passages between 3 and 8 were used in all experiments. Rapa-
mycin (purity: >98% HPLC) was purchased from Bio Basic (Mark-
ham, Ontario, Canada).
2.2. Method of choosing miRs for screening in the study
A PubMed search for the MeSH words ‘‘endothelial cells’’ and
‘‘microRNA’’ revealed that a total of 28 miRs and 1 miR cluster
had been reported to have connections with endothelial functions.
We selected 16 of these miRs, which may have been involved in
the regulation of endothelial cell proliferation or mobility, for fur-
ther experiments. The following miRs were selected: miR-19a,
miR-17-3p, miR-17-5p, miR-21, miR-31, miR-34a, miR-126, miR-
130a, miR-132, miR-155, miR-217, miR-221, miR-222, miR-23a,
miR-24, and miR-320. Of these miRs, miR-17-3p and miR-222 were
excluded from further work in the present study due to the non-
speciﬁcity of the primers that were used in qRT-PCR.
2.3. Quantitative RT-PCR
Total RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA,
USA), using the standard method. cDNA synthesis was performed
with 1 lg of total RNA, using the miScript II RT Kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. The se-
quences of primers speciﬁc to the published miR sequences can
be found in Table 1. Real-time PCR was performed on the ABI
7500 cycler (Applied Biosystems, CA, USA), using the miScript SYBR
Green PCR Kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s protocol. RNU6B and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) were used as endogenous controls for miRs
and mRNAs expression, respectively.
2.4. Small RNA transfection
miR-21 mimics/inhibitors, obtained from RiboBio (Guangzhou,
China), were transfected into HUVECs with the Hiperfect transfec-
tion reagent (Qiagen, Hilden, Germany) at a ﬁnal concentration of
50/100 nM (HUVECs). siRictor and siRaptor duplexes were syn-
thesized by GenePharma (Shanghai, China), and a non-silencing
siRNA was used as a negative control. The transfection protocol
for siRNA was the same as that for miR-21 mimics. Cells were
incubated with small RNA complexes for 6 h before the medium
was changed.Table 1
List of primers used in qRT-PCR.
Sense primers (50–30) Antisense primers (50–30)
miR-19a TGTGCAAATCTATGCAAAACTGA
Provided by miScript
SYBR Green PCR Kit
(Qiagen, Hilden, Germany)
miR-17-5p CAAAGTGCTTACAGTGCAGGTAG
miR-21 CGGTAGCTTATCAGACTGATGTTGA
miR-31 GCAAGATGCTGGCATAGCT
miR-34a GGCAGTGTCTTAGCTGGTTGT
miR-126 TCGTACCGTGAGTAATAATGCG
miR-130a CAGTGCAATGTTAAAAGGGCAT
miR-132 TAACAGTCTACAGCCATGGTCG
miR-155 TTAATGCTAATCGTGATAGGGGTA
miR-217 TACTGCATCAGGAACTGATTGGA
miR-221 AGCTACATTGTCTGCTGGGTTTC
miR-23a CACATTGCCAGGGATTTCC
miR-24 GCTCAGTTCAGCAGGAACAGA
miR-320 CTGGGTTGAGAGGGCGA
RhoB CCATCCGCAAGAAGCTGGA TCTTGGCAGAGCACTCGAGGTA
GAPDH GGGTGTGAACCATGAGAAGT GACTGTGGTCATGAGTCCT2.5. In vitro cell proliferation assay
Cell viability was assayed by a colorimetric procedure, using the
Cell Counting Kit-8 (Dojindo, Shanghai, China) according to the
manufacturer’s protocol. The absorbance at 460 nm was deter-
mined with a microplate reader. For each group, 5 duplicate wells
were detected per experiment. To detect the exact proliferation
rates of HUVECs, an EDU (5-ethynyl-20-deoxyuridine) incorpora-
tion assay was executed with the Cell-Light™ EdU In Vitro Imaging
Kit (Ribobio, Guangzhou, China) according to the producer’s
instructions. Brieﬂy, cells at 70–80% conﬂuence were treated with
50 lM EDU in ECM medium and incubated for 2 h before ﬁxation
in 4% paraformaldehyde. After EDU staining, cell nuclei were
stained with Hoechst 33342 and observed with an inverted ﬂuo-
rescent microscope (Olympus, Tokyo, Japan). For each group, 6 ran-
dom ﬁelds were photographed. The proliferation rate refers to the
number of EDU stained cells divided by the number of Hoechst
33342 stained cells.
2.6. In vitro wound healing assay
The HUVEC wound healing assay was performed as described
with minor modiﬁcations [19]. Brieﬂy, HUVECs were ﬁrst transfec-
ted with miR-21 mimics, inhibitors or negative control (NC) RNAs
in a 6-well plate and were allowed to grow overnight until conﬂu-
ent. Next, rapamycin was added to each well, except for the control
one, at a ﬁnal concentration of 100 ng/ml as a 24 h pre-treatment,
and this rapamycin treatment continued until the end of the test.
At the 0 h timepoint, the cell monolayer in each well was scraped
with a sterile 200 ll pipette tip 3 times to form parallel lines, fol-
lowed by 1 wash with ECM. The same wound areas were examined
and photographed with a Nikon Eclipse TS100 Microscope (Nikon,
Japan) at the 0 h and 24 h post-injury timepoints. The areas of the
cells that migrated into the wound ﬁelds were measured with
Adobe Photoshop software.
2.7. Boyden chamber migration assay
Transfected HUVECs that were treated as described for the
wound healing assay were pre-incubated for 24 h with 100 ng/ml
of rapamycin. The Boyden chamber assay was performed as de-
scribed previously [20]. Brieﬂy, 5  104 cells were loaded into the
upper chamber of a 8 lm pore size Millicell Culture Plate Insert
(Millipore, Billerica, USA) in 200 ll ECM that was supplemented
with 1% FBS. Rapamycin was diluted in ECM that was supple-
mented with 5% FBS to a ﬁnal concentration of 100 ng/ml, and
700 ll of this ﬁnal dilution were added to the lower chamber. Cells
were allowed to migrate for 3 h before ﬁxation in 4% paraformalde-
hyde, and those that had not migrated were removed from the
upper chamber surface with cotton swabs. Migrated cells on the
lower surface of the ﬁlter were stained with 40,6-diamidino-2-
phenylindole (DAPI) (Beyotime, Shanghai, China). Cells were ob-
served under a ﬂuorescent microscope (Olympus, Tokyo, Japan)
at 400 magniﬁcation and 6 random ﬁelds were photographed.
The average number of migrated cells in 6 random ﬁelds was taken
as the migration number for the group.
2.8. Western blots and antibodies
Cells in a 6-well plate were scraped in RIPA lysis buffer (Beyo-
time, Shanghai, China) that was supplemented with 1 mM PMSF.
Proteins (20 lg) were separated on 10% or 12% (for RhoB protein
assay) SDS–polyacrylamide gels and were electro-transferred to
polyvinylidene diﬂuoride (PVDF) membranes (Bio-Rad, Hercules,
CA). After a blocking incubation with 5% milk-TBST, the mem-
branes were incubated overnight in primary antibodies at appro-
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body that was conjugated to horseradish peroxidase (1:10000
dilution). After incubations in an enhanced chemiluminescence re-
agent (Amersham, Haemek, Israel), the images were captured on
the image reader LAS-4000 system (Fujiﬁlm, Tokyo, Japan).
Anti- Raptor, anti-Rictor and anti-RhoB for western blotting
were purchased from Cell Signaling Technology (Beverly, MA,
USA). Anti-GAPDH polyclonal antibody was purchased from Santa
Cruz Biotechnology (CA, USA).
2.9. Statistical analysis
All experiments were performed at least three times. Data were
presented as the means ± SEM. Analyses were conducted with SPSS
18.0 software, using the unpaired Student’s t-test for comparisons
between two groups or one-way ANOVA for multiple comparisons.
P values < 0.05 were considered statistically signiﬁcant.3. Results
3.1. miR-21 expression was upregulated by rapamycin treatment
We observed the effects of treatment with a typical rapamycin
concentration and time length (100 ng/ml, 24 h) on the expression
levels of all 14 miRs that were known to correlate with endothelial
cell function, according to previous studies. Changes greater than
2-fold were set as threshold levels. Among all the tested miRs,
we found that miR-21 had a fold change of 3.021 ± 0.4539, which
was beyond the threshold (Fig. 1A). We further veriﬁed the aug-
mented expression levels of miR-21 that were induced by rapamy-
cin. miR-21 expression was upregulated signiﬁcantly by rapamycin
in a time and dose dependent method when compared to the con-Fig. 1. (A) HUVECs were incubated with rapamycin (100 ng/ml) for 24 h. Several miRs w
expression levels of miR-21 were increased signiﬁcantly after rapamycin treatment. ⁄P <
of rapamycin for 24 h. Control cells were untreated. Vehicle cells were treated with dim
1000 ng/ml rapamycin. (C) Time-dependent effects of rapamycin (100 ng/ml) on relative
transfection with 50 nM miR-21 mimics, the mimic negative control (NC), or 100 nM introl, and had expression peaks at 24 h and 100 ng/ml, as deter-
mined by qRT-PCR (Fig. 1B and C).
3.2. Transfection of miR-21 mimics and inhibitors can attenuate the
level of miR-21
As shown in Fig. 1D, transfection with 50 nM miR-21 mimics
augmented miR-21 expression, while transfection with 100 nM
miR-21 inhibitors reduced miR-21 levels signiﬁcantly. None of
the negative control RNAs had a signiﬁcant effect.
3.3. Inhibition of miR-21 abrogates rapamycin-mediated inhibition of
endothelial proliferation
We detected cell viability with the CCK-8 test, which can indi-
rectly reﬂect the proliferative ability of the HUVECs. Rapamycin
treatment signiﬁcantly reduced HUVEC viability, while the down-
regulation of miR-21 by inhibitor treatment was able to recover
the absorbance values (Fig. 2A). A similar result was obtained with
the EDU incorporation assay. HUVEC proliferation rates were im-
paired by rapamycin treatment, but were renewed by miR-21
inhibitor transfection (Fig. 2B). The miR-21 mimic did not aggra-
vate the rapamycin mediated inhibition of endothelial prolifera-
tion when compared to rapamycin treatment alone, as was
revealed in both the CCK-8 test and the EDU incorporation assay
(Fig. 2A and B). The negative control RNAs for both the mimic
and the inhibitor had no signiﬁcant effects on cell proliferation.
3.4. Downregulation of miR-21 abolished the inhibitory effects of
rapamycin on endothelial migration
We examined the mobility of HUVECs with a wound healing
test and a Boyden chamber assay. In both assays, rapamycin inhib-ere detected by real-time PCR. Grid lines represent the fold changes of 2 or 0.5. The
0.05 compared to control. (B) HUVECs were incubated with different concentrations
ethyl sulfoxide (0.05%). ⁄P < 0.05 compared to control, #P < 0.05 compared to 1, 10,
miR-21 expressions. ⁄P < 0.05 compared to control. (D) Relative miR-21 levels after
hibitors or the inhibitor NC. ⁄P < 0.05 compared to control.
Fig. 2. In vitro cell proliferation assay. (A) Cell counting kit-8 assay. HUVECs were ﬁrst transfected with miR-21 mimics, inhibitors or the NC RNAs, and then 5  103 cells of
each group were seeded in a 96-well plate and cultured with 100 ng/ml rapamycin for 24 h. ⁄P < 0.05 compared to control, #P < 0.05 compared to all other groups except the
control. (B) EDU incorporation assay. Post-transfection HUVECs were pre-incubated with 100 ng/ml rapamycin and were cultured with 50 lM EDU-ECM medium for 2 h. In
the image overlay, the purple nuclei are EDU stained and indicate proliferating cells, while the blue nuclei are Hoechst 33342 stained. ⁄P < 0.05 compared to control, #P < 0.05
compared to all other groups except the control.
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controls, which was in accordance with previous studies [9,21].
Mimic-induced miR-21 upregulation revealed a similar yet more
effective inhibitory effect to rapamycin, but no statistical signiﬁ-
cance was observed when compared with rapamycin treatment.
However, when miR-21 expression was downregulated by anFig. 3. In vitro wound healing assay. Cells in a six-well plate were photographed at the
measured separately with Adobe Photoshop software by 2 different researchers. The ex
#P < 0.05 compared to all other groups except the control.inhibitor treatment, the mobility of HUVECs increased signiﬁcantly
in both the wound healing test and the Boyden chamber assay, as
comparing to rapamycin treatment, and even better than the con-
trol group as revealed in Boyden chamber assay. Neither the miR-
21 mimic NC nor the inhibitor NC had a signiﬁcant effect on the
regulation of rapamycin-inhibited HUVEC mobility. (Figs. 3 and 4).0 h and 24 h timepoints. The areas of cells that migrated to the wound zones were
periment was repeated 3 times with similar results. ⁄P < 0.05 compared to control,
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To identify the putative target of miR-21 that was involved in
the control of proliferation and migration, we searched several bio-
informatics databases, including miRanda, PicTar, and TargetScan.
These databases suggested that RhoB might be a target gene of
miR-21. The sequence position 1326–1332 in the RhoB 30UTR con-
tains a putative miR-21 binding site (Fig. 5A). By real-time RT-PCR
and western blotting, we identiﬁed that both RhoB mRNA and pro-
tein expression, respectively, were signiﬁcantly reduced by the
over-expression of miR-21 in response to miR-21 mimics, and in-
creased in response to miR-21 inhibitors. Rapamycin revealed a
similar effect to miR-21 mimics on RhoB protein expression,Fig. 4. Boyden chamber migration assay. Cells that were pre-treated as described wer
migrated cells were counted by Image J software. ⁄P < 0.05 compared with control, #P <although no signiﬁcant effect on RhoB mRNA levels was observed
(Fig. 5B and C).
3.6. Raptor knockdown (KD) attenuates the expression of miR-21
Because the mTORC1/2 signalling pathways are reported to
have key roles in the processes of rapamycin-impaired endothelial
proliferation and migration [21–23], we tested whether the
mTORC1/2 pathways participated in the regulation of miR-21. Rap-
tor and Rictor protein expression levels were reduced signiﬁcantly
by siRNA treatment, compared to the non-silenced group (Fig. 6A).
However, Rictor KD did not attenuate the expression of miR-21,
while Raptor KD did upregulate miR-21 expression (Fig. 6B).e seeded into the upper chamber and allowed to migrate for 3 h. The numbers of
0.05 compared to all other groups except the control.
Fig. 5. RhoB gene is a target of miR-21. (A) The alignment of potential miR-21 binding sites in the 30UTR of the RhoB mRNA. (B–C) After transfections, the mRNA and protein
expression levels of RhoB in HUVECs were reduced signiﬁcantly by miR-21 mimics and were augmented by miR-21 inhibitors. Cells that were pre-treated with rapamycin for
24 h revealed a similar inhibitory effect on RhoB protein expression to that of the miR-21 mimic, although no signiﬁcant effect was observed on RhoB mRNA levels. ⁄P < 0.05
compared to control.
Fig. 6. Rapamycin up-regulates miR-21 expression through the mTORC1 pathway. (A) Raptor and Rictor siRNA knockdown (KD). Western blot conﬁrms that Raptor and Rictor
expression levels were reduced by approximately 85% and 80% following siRNA treatment. (B) Relative miR-21 levels 24 h after Raptor and Rictor KD. MiR-21 expression was
signiﬁcantly upregulated by Raptor KD, while Rictor KD had no signiﬁcant effect. ⁄P < 0.05 compared to control.
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MiRs have been reported widely to be involved in endothelial
cell functions. In the present study, we tested the hypothesis that
rapamycin could inhibit the proliferation and migration of HU-
VECs, partly through a pathway that involved miRs. By qRT-PCR,
we found for the ﬁrst time that miR-21 was upregulated strikingly
by rapamycin treatment in a time and dose dependent manner.
Treatment with miR-21 inhibitors abrogates the rapamycin-medi-
ated inhibition of HUVEC proliferation and migration, which indi-
cates that miR-21 can mediate the rapamycin-induced inhibition
of endothelial growth and mobility.
miR-21 has been considered to be a main regulator in cell
growth and mobility; however, the conclusions are diverse. In
the cancer research ﬁeld, miR-21 was found to act as an oncogeneand to promote cell proliferation, invasion and migration [24–27].
Later studies revealed that in endothelial cells, the overexpression
of miR-21 could decrease cell apoptosis and increase eNOS activity
and nitric oxide production as a result of shear stress [28]. Direct
studies have been conducted on miR-21 and regulation of the pro-
liferation and migration of endothelial cells; however, the results
were controversial. Guduric-Fuchs et al. reported that the down-
regulation of miR-21 by LNA inhibitor reduced the proliferation,
migration, and tube-forming capacity of retinal microvascular
endothelial cells (RMECs) [29], while Sabatel et al. claimed that
miR-21 over-expression reduced the angiogenic capacity of HU-
VECs [13]. The reason for these contradictory results may be the
different cell types and the diverse target genes that were studied.
In our present study, we demonstrate that miR-21 has an anti-pro-
liferative and anti-migratory effect on rapamycin treated HUVECs.
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21 in the rapamycin induced inhibition of proliferation and migra-
tion, we focused on the identiﬁcation of target genes that were
potentially regulated by miR-21. Using qRT-PCR and western blot-
ting, our study revealed that RhoB is a target gene of miR-21. Pre-
vious studies published by Parikh et al. [30] and Sabatel et al. [13],
both of who constructed luciferase reporter vectors that encoded
the complete 30UTR of RhoB, demonstrated that miR-21 could bind
directly to the predicted site. Considering that the binding of miR-
21 to its target gene is universal in different cell types, the previous
data support our results.
The RhoB protein belongs to the Rho GTPase family, which con-
tains approximately 25 proteins, including the 3 most well known
members: RhoA, Rac1, and Cdc42. The Rho GTPase family has been
identiﬁed as a key regulator of angiogenesis through the modula-
tion of vascular permeability, migration and proliferation [31].
Some studies have investigated the relationship between RhoB
and endothelial cells. The deletion of RhoB was found to increase
endothelial apoptosis and impair endothelial cell migration and
tube formation [13,30,32], while the overexpression of RhoB in-
duced endothelial permeability and growth [33]. In line with these
studies, our present study indicates that RhoB acts as an anti-
angiogenic effector in the rapamycin mediated suppression of
endothelial proliferation and migration and that miR-21 plays a
key role in this process.
The connection between rapamycin and Rho GTPase has been
discussed previously, although the main focus was placed on RhoA,
a protein homologous to RhoB, and the conclusions were conﬂict-
ing. Guerin et al. discovered that RhoA activity in VSMC was in-
creased after rapamycin-eluted stents were implanted [34],while
other researchers claimed that rapamycin could suppress RhoA
protein synthesis and activity in several cancer cell lines via the
mTORC1-mediated S6K1 and 4E-BP1 pathways [22]. The mTORC2
pathway was also found to be involved in the regulation of RhoA.
Liu et al. discovered that the knockdown of Rictor led to a defect
in RhoA-GTP activation [35]. Moreover, Gulhati reported that the
inhibition of either mTORC1 or mTORC2 could suppress the activ-
ity of RhoA [36]. However, few data were found when we searched
for publications about rapamycin and RhoB. Our present study re-
veals for the ﬁrst time that rapamycin can suppress the protein
expression of RhoB through the upregulation of miR-21. RhoB
mRNA levels may not have been reduced signiﬁcantly by rapamy-
cin treatment because the fold change of miR-21 was not as large
as that which was induced by miR-21 mimics; however, rapamycin
seemed to reduce the efﬁciency of RhoB mRNA translation.
Our study also indicates that the rapamycin induced augmenta-
tion of miR-21 expression was likely a result of Raptor inhibition,
as was revealed in the Raptor KD experiment. In addition to reports
of targeting by several miRs [17,18], this was not the ﬁrst time that
mTORC componentswere reported to regulate the expression levels
of miRs. Sun et al. found that the expression of the muscle-speciﬁc
miR-1 was regulated by mTOR in differentiating myoblasts [37].
Ge et al. published that miR-125b biogenesis was negatively con-
trolled bymTOR signalling [38]. The furthermechanism of mTORC1
regulationofmiR-21 expression shouldbediscussed in later studies.
In short, our present work reveals that the expression of miR-21
in HUVECs was upregulated by rapamycin treatment and that
treatment with a miR-21 inhibitor totally abolished the suppres-
sive effects on endothelial proliferation and migration that were
induced by rapamycin. RhoB was found to be a direct target gene
of miR-21. The overexpression of miR-21 that was induced by rap-
amycin treatment was likely a result of Raptor inhibition. Finally,
considering that the depletion of miR-21 was found to inhibit the
proliferation of vascular smooth muscle cells (VSMCs) and to in-
crease apoptosis [39], will an anti-miR-21 treatment could have
the advantages of both anti-restenosis and improved re-endothel-ialization in rapamycin-eluted stents? This question should be ad-
dressed in future studies.Acknowledgments
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